IBDEI2UD ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,47686,1,4,0)
 ;;=4^C93.90
 ;;^UTILITY(U,$J,358.3,47686,2)
 ;;=^5001828
 ;;^UTILITY(U,$J,358.3,47687,0)
 ;;=C93.91^^209^2346^345
 ;;^UTILITY(U,$J,358.3,47687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47687,1,3,0)
 ;;=3^Monocytic Leukemia,Unspec,In Remission
 ;;^UTILITY(U,$J,358.3,47687,1,4,0)
 ;;=4^C93.91
 ;;^UTILITY(U,$J,358.3,47687,2)
 ;;=^5001829
 ;;^UTILITY(U,$J,358.3,47688,0)
 ;;=C93.92^^209^2346^344
 ;;^UTILITY(U,$J,358.3,47688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47688,1,3,0)
 ;;=3^Monocytic Leukemia,Unspec,In Relapse
 ;;^UTILITY(U,$J,358.3,47688,1,4,0)
 ;;=4^C93.92
 ;;^UTILITY(U,$J,358.3,47688,2)
 ;;=^5001830
 ;;^UTILITY(U,$J,358.3,47689,0)
 ;;=C94.00^^209^2346^3
 ;;^UTILITY(U,$J,358.3,47689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47689,1,3,0)
 ;;=3^Acute Erythroid Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47689,1,4,0)
 ;;=4^C94.00
 ;;^UTILITY(U,$J,358.3,47689,2)
 ;;=^5001834
 ;;^UTILITY(U,$J,358.3,47690,0)
 ;;=C94.01^^209^2346^2
 ;;^UTILITY(U,$J,358.3,47690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47690,1,3,0)
 ;;=3^Acute Erythroid Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47690,1,4,0)
 ;;=4^C94.01
 ;;^UTILITY(U,$J,358.3,47690,2)
 ;;=^5001835
 ;;^UTILITY(U,$J,358.3,47691,0)
 ;;=C94.02^^209^2346^1
 ;;^UTILITY(U,$J,358.3,47691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47691,1,3,0)
 ;;=3^Acute Erythroid Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47691,1,4,0)
 ;;=4^C94.02
 ;;^UTILITY(U,$J,358.3,47691,2)
 ;;=^5001836
 ;;^UTILITY(U,$J,358.3,47692,0)
 ;;=C94.20^^209^2346^12
 ;;^UTILITY(U,$J,358.3,47692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47692,1,3,0)
 ;;=3^Acute Megakaryoblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47692,1,4,0)
 ;;=4^C94.20
 ;;^UTILITY(U,$J,358.3,47692,2)
 ;;=^5001837
 ;;^UTILITY(U,$J,358.3,47693,0)
 ;;=C94.21^^209^2346^11
 ;;^UTILITY(U,$J,358.3,47693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47693,1,3,0)
 ;;=3^Acute Megakaryoblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47693,1,4,0)
 ;;=4^C94.21
 ;;^UTILITY(U,$J,358.3,47693,2)
 ;;=^5001838
 ;;^UTILITY(U,$J,358.3,47694,0)
 ;;=C94.22^^209^2346^10
 ;;^UTILITY(U,$J,358.3,47694,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47694,1,3,0)
 ;;=3^Acute Megakaryoblastic Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47694,1,4,0)
 ;;=4^C94.22
 ;;^UTILITY(U,$J,358.3,47694,2)
 ;;=^5001839
 ;;^UTILITY(U,$J,358.3,47695,0)
 ;;=C94.30^^209^2346^298
 ;;^UTILITY(U,$J,358.3,47695,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47695,1,3,0)
 ;;=3^Mast Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,47695,1,4,0)
 ;;=4^C94.30
 ;;^UTILITY(U,$J,358.3,47695,2)
 ;;=^5001840
 ;;^UTILITY(U,$J,358.3,47696,0)
 ;;=C94.31^^209^2346^297
 ;;^UTILITY(U,$J,358.3,47696,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47696,1,3,0)
 ;;=3^Mast Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,47696,1,4,0)
 ;;=4^C94.31
 ;;^UTILITY(U,$J,358.3,47696,2)
 ;;=^5001841
 ;;^UTILITY(U,$J,358.3,47697,0)
 ;;=C94.32^^209^2346^296
 ;;^UTILITY(U,$J,358.3,47697,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47697,1,3,0)
 ;;=3^Mast Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,47697,1,4,0)
 ;;=4^C94.32
 ;;^UTILITY(U,$J,358.3,47697,2)
 ;;=^5001842
 ;;^UTILITY(U,$J,358.3,47698,0)
 ;;=C94.40^^209^2346^30
 ;;^UTILITY(U,$J,358.3,47698,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,47698,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,47698,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,47698,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,47699,0)
 ;;=C94.41^^209^2346^28
 ;;^UTILITY(U,$J,358.3,47699,1,0)
 ;;=^358.31IA^4^2
